Baseline IL-17 and IL-23 were higher in patients with active LN than in those with inactive LN or controls (P < 0.001). IL-17 kept an inverse correlation with C3 (r = −0.44, P < 0.001). IL-17 and IL-23 decreased significantly in active LN patients after 6 months of therapy (P < 0.001). The baseline level of IL-23 was a predictor of response to the immunosuppressive treatment in patients with active LN, being lower in the complete response than in the partial response group (P = 0.0015) or non-response group (P = 0.013). IL-17 and IL-23 correlated with SLEDAI (P < 0.001). The gene discussed is IL37; the disease is lobular neoplasia.